cognitotx.comCrawled Oct 14, 2026
The page features recent press, publications, and announcements about Cognito and its Alzheimer’s treatment.
Cognito is creating more treatment options for Alzheimer’s patients.
Cognito is creating novel therapeutics that improve the lives of patients living with neurodegenerative diseases.
Cognito is developing disease-modifying treatments to revive the health and well-being of patients living with Alzheimer’s.
Cognito Therapeutics secures $105 million in Series C funding to advance its neurotechnology platform. The company develops treatments for neurodegenerative disorders using visual and auditory stimulation techniques. This round was oversubscribed, indicating strong investor interest in its approach.
Oct 2026MobiHealthNewsNews article
Rhode Island Life Science Hub and Cognito Therapeutics have launched a **Brain Health Collaboratory**, a statewide platform aimed at accelerating innovation, research, and care for **Alzheimer’s disease**. The initiative combines resources to foster breakthroughs in brain health technologies and therapeutic solutions. The partnership focuses on leveraging collective expertise to develop new approaches in Alzheimer’s treatment and prevention.
Oct 2026PR NewswireNews article
Ochsner Health is testing an experimental at-home treatment for Alzheimer’s disease that may also address other neurological conditions. The initiative aims to expand access to novel therapies in Louisiana, potentially benefiting patients with neurodegenerative disorders.
Jul 2026https://www.fox8live.comNews article
BrightFocus Foundation funds **The HOPE Study**, which investigates a non-invasive therapy combining light and sound stimulation as a potential treatment for Alzheimer’s disease. Researchers evaluate whether this approach can improve cognitive function or slow progression in participants. The study aims to explore alternative interventions beyond conventional pharmaceutical methods.
Aug 2024BrightFocus FoundationNews article
